Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, PR China.
Oncol Rep. 2012 Feb;27(2):447-54. doi: 10.3892/or.2011.1482. Epub 2011 Oct 3.
microRNAs (miRs) are endogenous small non-coding RNAs that are aberrantly expressed in various carcinomas. miR-152 and miR-148a have not been comprehensively investigated in ovarian cancer. Thus, the aim of this study was to identify the role of miR-152 and miR-148a in epithelial ovarian cancer. Total RNA was extracted from tissues of 78 patients with epithelial ovarian cancer, 17 normal ovarian epithelium tissues and two ovarian cancer cell lines. Using quantitative real-time PCR (qRT-PCR) followed by the 2-ΔΔCT method for calculating the results, we found that the expression levels of miR-152 were significantly decreased in ovarian cancer tissues compared to normal ovarian epithelium tissues (p<0.05). However, although the expression of miR-148a was also decreased in 65% of patients, no statistically significant difference in expression was found. A strong correlation was found between the expression of miR-152 and miR-148a (p<0.001, Pearson's correlation). The relationship between miR-152 or miR-148a expression levels in ovarian cancer and clinicopathological features, response to therapy and short-term survival was analyzed and the results showed that no correlation existed. In addition, we found that both miR-152 and miR-148a were down-regulated in ovarian cancer cell lines. After miR-152 or miR-148a mimics were transfected into ovarian cancer cell lines, the MTT cell proliferation assay showed that cell proliferation was significantly inhibited. Taken together, miR-152 and miR-148a may be involved in the carcinogenesis of ovarian cancer through deregulation of cell proliferation. They may be novel biomarkers for early detection or therapeutic targets of ovarian cancer.
微小 RNA（miRs）是内源性的小非编码 RNA，在各种癌中表达异常。miR-152 和 miR-148a 在卵巢癌中尚未得到全面研究。因此，本研究旨在探讨 miR-152 和 miR-148a 在卵巢上皮性癌中的作用。从 78 例上皮性卵巢癌患者、17 例正常卵巢上皮组织和 2 种卵巢癌细胞系的组织中提取总 RNA。采用定量实时 PCR（qRT-PCR）并通过 2-ΔΔCT 方法计算结果，我们发现 miR-152 在卵巢癌组织中的表达水平明显低于正常卵巢上皮组织（p<0.05）。然而，尽管 miR-148a 的表达在 65%的患者中也降低，但表达水平没有统计学差异。miR-152 和 miR-148a 的表达之间存在很强的相关性（p<0.001，Pearson 相关性）。分析了 miR-152 或 miR-148a 在卵巢癌中的表达水平与临床病理特征、对治疗的反应和短期生存之间的关系，结果表明两者之间无相关性。此外，我们发现 miR-152 和 miR-148a 在卵巢癌细胞系中均下调。将 miR-152 或 miR-148a 模拟物转染入卵巢癌细胞系后，MTT 细胞增殖试验显示细胞增殖明显受到抑制。总之，miR-152 和 miR-148a 可能通过调节细胞增殖参与卵巢癌的发生。它们可能是卵巢癌早期检测或治疗靶点的新型生物标志物。
